Miyata T, Ueda Y, Shinzato T, Iida Y, Tanaka S, Kurokawa K, van Ypersele de Strihou C, Maeda K
Department of Internal Medicine, Branch Hospital, Nagoya University School of Medicine, Japan.
J Am Soc Nephrol. 1996 Aug;7(8):1198-206. doi: 10.1681/ASN.V781198.
Pentosidine is an advanced glycation end product and its formation is shown to be closely related to oxidative processes. Recent studies have shown that pentosidine levels are increased not only in plasma and matrix proteins from diabetic patients, but also markedly in nondiabetic hemodialysis patients. Currently, the mechanism of accumulation and kinetics of pentosidine formation in hemodialysis patients remain unknown. Gel filtration of uremic plasma revealed that plasma pentosidine exists in the albumin fraction (approximately 90%) and, interestingly, in free form (approximately 5%) as well. Plasma free pentosidine was undetectable in subjects with normal renal function. There was a significant correlation between the plasma levels of albumin-linked and free pentosidine in hemodialysis patients. Kinetic studies indicated that dietary pentosidine was absorbed into the circulation and that, after either oral or intravenous administration of pentosidine to intact or nephrectomized rats, the plasma free pentosidine level was closely linked to the level of renal function. These findings demonstrate that: (1) Pentosidine accumulates as albumin-linked and in free form in the circulation of uremic patients; (2) dietary pentosidine can be absorbed into the circulation, thus being one possible origin of circulating free pentosidine; (3) free pentosidine may accumulate as a result of decreased glomerular filtration; and (4) the mechanism of accumulation of albumin-linked pentosidine is not related to high glucose levels. It suggests the simultaneous accumulation, during renal failure, of either unknown pentosidine precursor(s) or catalyst(s) of glycoxidation, independent of glucose.
戊糖苷是一种晚期糖基化终产物,其形成与氧化过程密切相关。最近的研究表明,戊糖苷水平不仅在糖尿病患者的血浆和基质蛋白中升高,在非糖尿病血液透析患者中也显著升高。目前,血液透析患者中戊糖苷积累的机制及其形成动力学仍不清楚。对尿毒症血浆进行凝胶过滤分析发现,血浆戊糖苷存在于白蛋白部分(约90%),有趣的是,也以游离形式存在(约5%)。肾功能正常的受试者血浆中未检测到游离戊糖苷。血液透析患者血浆中与白蛋白结合的戊糖苷和游离戊糖苷水平之间存在显著相关性。动力学研究表明,膳食中的戊糖苷可被吸收进入循环系统,并且在给完整或肾切除大鼠口服或静脉注射戊糖苷后,血浆游离戊糖苷水平与肾功能水平密切相关。这些发现表明:(1)在尿毒症患者的循环系统中,戊糖苷以与白蛋白结合和游离形式积累;(2)膳食中的戊糖苷可被吸收进入循环系统,因此是循环游离戊糖苷的一个可能来源;(3)游离戊糖苷可能由于肾小球滤过率降低而积累;(4)与白蛋白结合的戊糖苷积累机制与高血糖水平无关。这表明在肾衰竭期间,存在未知的戊糖苷前体或糖氧化催化剂同时积累,且与葡萄糖无关。